Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CANbridge Sponsors Gene Therapy Research for Duchenne Muscular Dystrophy

publication date: Nov 4, 2021

CANbridge, a Beijing rare disease biopharma, announced a two-year sponsored gene therapy research agreement for Duchenne muscular dystrophy, a rare childhood neuromuscular disease. CANbridge will fund research at the University of Washington in Seattle that will be directed by Jeffrey Chamberlain, PhD, professor in the Departments of Neurology, Medicine and Biochemistry. Dr. Chamberlain is well-known for his research into the use of gene therapies for muscle diseases. In particular, his lab has been studying muscular dystrophy mechanisms, including dystrophin structure, and gene therapy approaches. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital